Home Cart Sign in  
Chemical Structure| 1234356-69-4 Chemical Structure| 1234356-69-4

Structure of Derazantinib
CAS No.: 1234356-69-4

Chemical Structure| 1234356-69-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Derazantinib is a fibroblast growth factor receptor (FGFR) inhibitor that has antitumor activity.

Synonyms: ARQ-087

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Derazantinib

CAS No. :1234356-69-4
Formula : C29H29FN4O
M.W : 468.57
SMILES Code : COCCNCCC1=CC(NC2=NC=C3C[C@@H](C4=CC=CC=C4F)C5=CC=CC=C5C3=N2)=CC=C1
Synonyms :
ARQ-087
MDL No. :MFCD30532770
InChI Key :KPJDVVCDVBFRMU-AREMUKBSSA-N
Pubchem ID :46834118

Safety of Derazantinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Derazantinib

RTK

Isoform Comparison

Biological Activity

Target
  • FGFR2

    FGFR2, IC50:1.8 nM

  • FGFR3

    FGFR3, IC50:4.5 nM

  • FGFR4

    FGFR4, IC50:34 nM

  • FGFR1

    FGFR1, IC50:4.5 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Keloid fibroblasts (KFs) 2.5 μmol/L 48 hours Derazantinib significantly suppressed the expression of PAI-1, FGFR1, collagen I, and α-SMA in KFs. PMC10741236
Keloid fibroblasts (KFs) 2.5 μmol/L 48 hours Derazantinib significantly inhibited the migration and invasion capability of KFs. PMC10741236
Keloid fibroblasts (KFs) 0, 0.16, 0.31, 0.63, 1.25, 2.5, 5 μmol/L 48 hours Derazantinib significantly inhibited the proliferation of KFs in a dose-dependent manner. Treatment with derazantinib at 5 μmol/L almost completely wiped off the KFs. PMC10741236
Human keloid fibroblasts (KFs) 2.5 μmol/L 48 hours Derazantinib significantly downregulated the expression of PAI-1, α-SMA, and collagen I, and inhibited the AKT and ERK signaling pathways. PMC10741236
Human keloid fibroblasts (KFs) 2.5 μmol/L 48 hours Derazantinib significantly inhibited the migration and invasion capabilities of KFs. PMC10741236
Human keloid fibroblasts (KFs) 0, 0.16, 0.31, 0.63, 1.25, 2.5, 5 μmol/L 48 hours Derazantinib significantly inhibited the proliferation of KFs in a dose-dependent manner, with 5 μmol/L concentration almost completely eliminating KFs. 2.5 μmol/L concentration showed significant inhibition on KFs but not on normal skin fibroblasts (Fbs). PMC10741236
NCI-H716, SNU-16, KATO-III 0 to 3 μM 2 hours To evaluate the inhibitory effect of ARQ 087 on the FGFR signaling pathway PMC5023172
COS-1 cells 0.123 μM, 0.185 μM, 0.463 μM, >10 μM 2 hours To evaluate the inhibitory effect of ARQ 087 on the phosphorylation of FGFR1, FGFR2, FGFR3, and FGFR4 PMC5023172

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude mice AN3CA xenograft model Oral 50-75 mg/kg Once daily for 12 days Evaluate the combined antitumor activity of ARQ 092 and ARQ 087, results showed significantly enhanced tumor growth inhibition PMC5404396
BALB/C female athymic nude mice Keloid xenografts Local injection 1 mg/mL and 2 mg/mL Once a week for four weeks Derazantinib significantly reduced the weight of the transplanted keloids, inhibited collagen production, and disrupted angiogenesis. PMC10741236
NCr nu/nu mice SNU-16 and NCI-H716 xenograft models Oral 50 mg/kg and 75 mg/kg Once daily for 14 days To evaluate the anti-tumor effect of ARQ 087 in FGFR2-driven tumor models PMC5023172
Zebrafish embryos Tg(fli1a:EGFP)y1 transgenic zebrafish Added to embryo water 0.1-3 μM Treatment started at 6-8 hours post-fertilization To investigate the effect of DZB on blood vessel morphogenesis, it was found that DZB interferes with multiple angiogenic processes linked to FGF and VEGF signaling, revealing its potential dual role as a potent anti-angiogenic treatment. PMC7824571
Sprague-Dawley (SD) rats No specific model used Oral 30 mg/kg Single dose To study the drug-drug interaction between derazantinib and naringin, results showed no significant effect of naringin pretreatment on the pharmacokinetic parameters of derazantinib PMC10013357

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.13mL

0.43mL

0.21mL

10.67mL

2.13mL

1.07mL

21.34mL

4.27mL

2.13mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories